{"denoms":[{"counts":[{"groupId":"BG000","value":"273"},{"groupId":"BG001","value":"275"},{"groupId":"BG002","value":"53"},{"groupId":"BG003","value":"53"},{"groupId":"BG004","value":"654"}],"units":"Participants"}],"groups":[{"description":"Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"BG000","title":"FL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"BG001","title":"MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"BG002","title":"FL: Placebo + Rituximab + Lenalidomide"},{"description":"Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"BG003","title":"MZL: Placebo + Rituximab + Lenalidomide"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.89","value":"64.6"},{"groupId":"BG001","spread":"11.69","value":"63.7"},{"groupId":"BG002","spread":"10.69","value":"68.3"},{"groupId":"BG003","spread":"11.40","value":"67.9"},{"groupId":"BG004","spread":"11.33","value":"64.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"126"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"26"},{"groupId":"BG004","value":"302"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"27"},{"groupId":"BG004","value":"352"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"67"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"228"},{"groupId":"BG001","value":"226"},{"groupId":"BG002","value":"45"},{"groupId":"BG003","value":"41"},{"groupId":"BG004","value":"540"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"47"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"219"},{"groupId":"BG001","value":"219"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"41"},{"groupId":"BG004","value":"522"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"}],"title":"Black or African-American"},{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"95"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"28"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"6"}],"title":"Captured as \"Other\" in Database"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}